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Introduction
Gap junctions are intercellular membrane channels
connecting directly the cytoplasm of adjacent cells for
the exchange of inorganic ions, second messengers
and small metabolites (<1kDa) [1]. Gap junctional
intercellular communication (GJIC) is involved in tis-
sue development, maintenance of tissue homeostasis
and morphogenesis and it affects cell differentiation
and proliferation by regulation of signal transduction
and cell cycle [2]. Gap junction channels are con-
structed of assemblies of oligomeric proteins called
connexins (Cxs). These proteins are synthesized,
joined in hexamers, called connexons, and aligned
with the connexon of the adjacent cell membrane to
form a channel [3]. Gap junctional communication is
subject to regulation by numerous substances, such as
growth factors, Ca2+ and hormones, also involved in the
synthesis and recruitment of connexins [4,5]. Connexins
are encoded by different genes and until now more that
20 connexins have been recognized in human [6]. It has
been shown that Cx26 and Cx32 are expressed in
human endometrial glandular epithelium, whereas Cx43
is present in endometrial stromal cells [7]. Expression of
Cx26 and Cx32 changes significantly during the men-
strual cycle: weak expression in the proliferative phase,
markedly elevated during ovulation and most pro-
nounced in the mid-secretory phase. 
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menopausal women. In the normal endometrium punctate, membrane-associated immunoreactivity for Cx26 was observed.
54 of 73 endometrial cancers showed Cx26 expression, but 46/54 (85%) immunopositive sections revealed cytoplasmic
localization for Cx26 with granular or occasionally diffuse immunostaining pattern. In addition, part of Cx26-positive
tumours showed mixed: cytoplasmic and membranous staining pattern and focally also nuclear or perinuclear immunos-
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cers strong reaction was noted. We did not find relationship between Cx26 expression and patients' age, histological type of
cancer and histological grade, nevertheless we observed positive association between Cx26 expression and tumour size
(p=0.037). In conclusion, our results suggest that transformed malignant cells continue to produce Cx26, which are proba-
bly not assembled into functional gap junction channels, but could still play other roles in endometrial cancer cells.
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There is substantial evidence that interruption of
gap junctional communication is an important step
ahead towards malignant transformation [8-10]. Most
normal cells have functional intercellular communica-
tion, while most, if not all, tumour cells have dysfunc-
tional GJIC [11,12]. Decreased communication via
gap junctions may be an important event in the onco-
genesis. Reversely, reconstitution of gap channels has
been shown to restore normal phenotypes and to retard
tumour cell growth. It was thus suggested that genes
encoding connexins could play a tumour suppressing
role [13,14]. Endometrial cancer is worldwide the
most often diagnosed gynaecological malignancy and
its frequency is increasing in the developed countries.
It has been reported that during endometrial carcino-
genesis, loss of GJIC may occur as a result of
decreased expression and aberrant localization of Cxs
[15]. Nevertheless, knowledge about possible role of
Cxs in human endometrial carcinogenesis is very lim-
ited. Furthermore, correlation between connexin
expression and anatomoclinical features in endometri-
al cancer has not yet been investigated. Consequently,
the aim of the present study was to evaluate expression
and localization of Cx26 by immunohistochemistry in
normal endometrium and in endometrial cancer speci-
mens as well as to estimate the relationships between
assessed connexin and selected anatomoclinical fea-
tures.
Material and methods
Patients and tissue specimens. Tissue samples were obtained
from 73 women treated surgically for primary endometrial cancer.
The patients' age ranged from 37 to 83 years (mean 61.9 years).
Tumour samples were collected shortly after tumour removal,
fixed in 10% buffered formaldehyde solution for 48h and then
embedded in paraffin blocks at 56°C according to standard proce-
dures. 5 µm sections were cut from the specimens and stained with
haematoxylin-eosin. The diagnosis was based on the World Health
Organization (WHO) classification of endometrial tumours. Our
study included 67 endometrial cancers classified histopathologi-
cally as endometrioid adenocarcinoma and 6 as endometrioid ade-
nocarcinoma with squamous metaplasia. 12 (16.4%) cases were
classified as G1 grade (well-differentiated adenocarcinoma), 50
(68.5%) cases as G2 (moderately differentiated adenocarcinoma)
and 11 (15.1%) cases as G3 (poorly differentiated adenocarcino-
ma). Staging was done according to the International Federation of
Gynaecology and Obstetrics (FIGO) system. This resulted in 5 IA
cases, 30 - IB, 27 - IC, 7 - IIA, 3 - IIB, and 3 - IIIA.
Twenty sections of normal endometrial tissues in various phas-
es of the menstrual cycle (proliferative and secretory), obtained
from premenopausal women undergoing hysterectomy for myoma
uteri or early invasive sqamous cell carcinoma of the cervix (IA1
by the FIGO classification) were the control group. 
Immunohistochemistry. Paraffin-embedded tissue sections were
subjected to immunostaining using goat polyclonal Cx26 antibody
(Santa Cruz Biotechnology, USA) in dilution rate 1:100. Primary
antibody was diluted in PBS with 1.5% normal blocking serum. A
streptavidin-biotin-peroxidase complex technique was used to
reveal antibody-antigen reactions (LSAB kit, Dako, Denmark).
Immunohistochemistry was performed as described previously
[16]. Slides were counterstained with haematoxylin. Following
immunohistochemical controls were performed: normal
endometrium was used as a positive control [7]; negative control
included omission of the primary antibody. The evaluation of
immunostaining for studied protein was analyzed in 10 different
tumour fields and the mean percentage of tumour cells with posi-
tive staining was evaluated. The expression of Cx26 in cancer sam-
ples was classified using a scale: 0 (negative cases) less than 10%
of positive cells; 1+ with immunoreactivity ranging from 10% to
50% of positive cancer cells; 2+ with over 50% of positive cells.
Statistical analysis. The relationship between Cx26 expression
and studied clinicopathological features was evaluated with the χ2
(Chi-square) test. Probabilities of p<0.05 were considered statisti-
cally significant.
Results
Expression and localization of Cx26 in normal
endometrium and endometrial cancer
In normal human endometrium mainly intercellular
granular localization of immunostaining pattern was
observed only in endothelial cells of endometrial glan-
dular epithelium, but not in the surrounding stroma or
myometrium. The expression of Cx26 was most
intense in the late proliferative phase and in the early
secretory phase of the menstrual cycle (Fig. 1). The
studied marker was not detected in control samples,
where immunostaining was performed with the omis-
sion of the primary antibody.
In the endometrial cancer 54 of total 73 samples
(74%) were positive for Cx26. In 21/54 (39%) of
Cx26-positive cases weak staining pattern was seen,
however in 33/54 (61%) cancers there was a strong
reaction. Immunohistochemical analysis revealed
cytoplasmic localization of Cx26 in 46/54 (85%)
immunopositive sections with granular or occasional-
ly diffuse immunostaining pattern (Fig. 2A, 2B, 2C).
In these cases sporadically and focally membranous
staining was present. The samples that showed diffuse
cytoplasmic reaction for Cx26 were carcinomas in G3
grade (Fig 2A, C). In 8/54 (15%) of Cx26-positive
tumours, classified as G1 grade, mixed reaction: cyto-
plasmic and punctate, membrane-associated was seen.
(Fig. 2D) Focally nuclear or perinuclear immunoreac-
tivity for Cx26 was also noted in some samples (Fig.
2A, 2C).
Correlations between Cx26 expression and
anatomoclinical features
To study the relationship between Cx26 and anato-
moclinical features such as: histological grade (G1, G2
and G3), tumour size, histopathological type (adeno-
carcinoma and adenocarcinoma with squamous meta-
plasia) and age (≤60 and >60), a total number of 73
cases of endometrial cancer were examined. 
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Fig. 1. Expression and localization of Cx26 in normal endometrium.(A, B) Mainly intercellular localization of the granular immunos-
taining pattern only in the endothelial cells of endometrial glandular epithelium in late proliferative phase of the menstrual cycle. (C, D)
Immunopositive granular deposits of Cx26 distributed between epithelial cells of endometrium in early secretory phase of the menstrual
cycle.
Fig. 2. Expression and localization of Cx26 in endometrial cancer. (A) Strong cytoplasmic immunostaining of Cx26 in endometrial can-
cer cells, focally perinuclear immunoreactivity. (B) Strong cytoplasmic immunostaining of Cx26 in the majority cells of G2 grade
endometrial cancer. (C) Diffuse or granular cytoplasmic reaction in G3 endometrial cancer, focally also nuclear or perinuclear immunos-
taining. (D) Punctate Cx26 immunostaining densely distributed mainly between cancerous cells.
The expression of Cx26 was not associated with
age, histological grade and histopathological type of
tumour. However, there was an indication for positive
correlation with statistical significance between Cx26
expression and tumour size (p=0.037), although posi-
tive immunostaining for Cx26 appeared more fre-
quently in advanced tumour stages (cancer invading
more than halfway into the myometrium or from the
body of the uterus to the cervix) than in tumours which
spread less than halfway through the myometrium.
Discussion
In the present study we examined immunohistochemi-
cally the expression of Cx26 in normal human
endometrium and in the endometrioid adenocarcinoma
of the uterus. We observed mainly membranous gran-
ular immunostaining for this protein in endothelial
cells of normal endometrial glandular epithelium, but
not in the surrounding stroma or myometrium. These
results are compatible with the results of the previous
study by Saito et al. [7], who analyzed the distribution
of Cx26 and Cx32 in human endometrial glandular
epithelium as well as changes in the expression of
these proteins during the reproductive cycle.
Carcinogenesis is a multistage process and differ-
ent pathways can lead to cancer [17]. Decreased
expression of Cxs and alterations in GJIC correlate
with tumourigenesis [18-20]. Connexins are typically
localized in the cell membrane and normally show a
punctate pattern of expression [21,22]. Aberrant local-
ization of connexins was revealed in several types of
tumours in our and other studies [15,20,23,24] and it
might result in the intercellular communication loss
via gap junction channels. In the present study, we
demonstrated changes in the Cx26 expression and
localization, which manifested in decreased expression
and mainly cytoplasmic localization of this protein in
the endometrial cancer cells. Disturbed expression and
subcellular localization of this protein in our study is
consistent with previous observations made by Saito et
al. [15], who showed that during endometrial carcino-
genesis suppressed expression and aberrant localiza-
tion of Cx26 and Cx32 may occur at relatively early
stages. 
Our previous observations [20,25] and present
results suggest that cells may depend on the distur-
bances in the synthesis and subcellular localization of
Cx26, but mechanisms responsible for these changes
are still little known. Only one connexin gene mutation
in human tumours has been described so far (advanced
stages of human sporadic colon cancer) [26]. On the
other hand, there is growing body of evidence sug-
gesting that connexin genes could be inactivated by
hypremethylation of their promoter regions [27]. It is
probable that this epigenetic inactivation of connexin
genes may be one of the causes of decreased expres-
sion of connexins in the endometrial cancer, however
it requires detailed studies. 
Another important problem, which warrants further
explanation, is the aberrant subcellular (cytoplasmic or
nuclear) localization of connexins in cancerous cells,
observed also in this study. It has been well document-
ed that cell-cell adhesion is necessary for the formation
of functional gap junction channels [8]. Cadherins and
catenins are involved in the creation of adherens junc-
tions. Dysfunction of these proteins may result in the
decreased membrane expression of Cxs. It has been
reported that β-catenin was localized in the nucleus in
endometrial hyperplasia and cancer [28]. Additional
observations made by Shih et al. [29] have shown that
the expression of E-cadherin and cytoplasmic β-
catenin in endometrial carcinomas decreased com-
pared to normal proliferative endometrial glands.
Moreover, the expression of E-cadherin and cytoplas-
mic β-catenin tends to be reduced in histologically
high-grade tumours, compared to low-grade tumours.
Additionally, we have recently demonstrated that dur-
ing colorectal carcinogenesis altered expression and
localization of connexins, E-cadherin and β-catenin is
a common phenomenon. Furthermore, we noted the
statistically significant correlation between expression
of examined connexins and adhesion proteins (data not
shown). This may suggest close relations between
these proteins. Additionally, it is possible that changes
in the expression of adhesion proteins might contribute
to the incorrect localization of connexins in the can-
cerous cells.
Cx26 protein accumulates in the cytoplasm of can-
cer cells and plays a role different from its physiologi-
cal one. Krutovskikh et al. [30] discovered that sub-
cellular localization of Cx43 in tumour cells could play
a role in the regulation of tumour growth. Recently,
Olbina et al. [31] showed that changes in protein
sequence of the second extracellular region of Cx43
prevent incorporation of the protein into the plasma
membrane, but do not decrease its ability to inhibit the
growth of tumour cells in vitro. They concluded that
regulation of cellular growth by Cx43 does not neces-
sarily require well-functioning gap junctions. It is pos-
sible that connexins in the intracellular (cytoplasmic or
nuclear) compartment may control tumour progression
modulating expression of the genes responsible for
cell growth regulation, differentiation and apoptosis as
well as other functions of cancerous cells. These find-
ings show that connexins localized in the cytoplasm
and between cells can play different roles in the cell
signalling pathways. Several reports described growth
suppression in the absence of functionally coupled
channels [32,33]. For example, Qin et al. [32] found
that tumour-suppressing properties of connexins in
breast cancer cell lines were independent from gap
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junction communication. They suggested that it could
be a result of down-regulation of genes involved in
tumour growth, such as the gene encoding fibroblast
growth factor receptor-3 [32]. Furthermore, Zhang et
al. [33] revealed a gap junction-independent suppres-
sion of tumour growth. They demonstrated that Cx43
in osteosarcoma cell line inhibited expression of S
phase kinase-associated protein 2 (Skp2), which was
responsible for p27 ubiquitination. Zhang et al. [33]
supposed that Cx43 localized in cytoplasmic or
nuclear cell compartment could indirectly take part in
the degradation of this protein regulating the expres-
sion of other genes. Moreover, Cx43 expression was
associated for example with an increased expression of
cyr61, an immediate early gene encoding a cysteine-
rich heparin-binding protein, which seems to be
involved in several cellular pathways including growth
and differentiation [34].
In the present study we have also analyzed the cor-
relation between Cx26 expression and some clinico-
pathological features. We found that in advanced
tumour stages (cancer spread more than halfway
through the myometrium or from the body of the
uterus to the cervix), more Cx26 positive cases were
present than in tumours which spread less than
halfway through the myometrium. It is hard to com-
ment on these findings because statistical significance
was not strong and an association between Cxs expres-
sion and anatomoclinical features in endometrial can-
cer has not yet been investigated. Nevertheless, in our
recent studies on connexin and adhesion proteins
expression in colorectal cancer, we observed an analo-
gous correlation between Cx32 expression and tumour
size, but only in the subgroup of patients without
metastases to lymph nodes (data not shown). On the
other hand, it is important to note that in malignant
cells synthesized Cxs are localized mainly in cyto-
plasm, which was observed also in this study. In this
instance, it may suggest that increased expression of
Cx26 in the most advanced stages of cancer might be
a result of long-term development of cancerous cells
and longer period of protein synthesis and/or
decreased tumour cell turnover because of disturbed
apoptosis. We suppose that Cxs, despite its well known
role in the stimulation of apoptosis, could also interact
with antiapoptotic proteins. Recently, in our immuno-
histochemical study on Cx26 and apoptotic markers
expression in colorectal cancer, we revealed the posi-
tive correlation between Cx26 and antiapoptotic pro-
tein - Bcl-xL [35]. The association between Cx26 and
Bcl-xL expression in colorectal cancer cells might
partly explain this theory, but additional functional
studies on the role of connexins in these processes are
required.
In conclusion, results of our study may suggest that
endometrial cancer cells continue to produce connexin
26, which is probably not assembled into functional
gap junction channels, however it still plays an impor-
tant roles in the transformed malignant cells.
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